» Articles » PMID: 32988598

Factors Contributing to Vitamin D Status at Hospital Admission for Pulmonary Exacerbation in Adults With Cystic Fibrosis

Overview
Journal Am J Med Sci
Publisher Elsevier
Specialty General Medicine
Date 2020 Sep 29
PMID 32988598
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Individuals with cystic fibrosis (CF) have difficulty maintaining optimal vitamin D status due to pancreatic insufficiency-induced malabsorption, inadequate sunlight exposure, and poor intake of vitamin D containing foods. Vitamin D deficiency may increase the risk of pulmonary exacerbations of CF. The objective of this study was to assess factors impacting vitamin D status in patients with CF recently hospitalized for a pulmonary exacerbation of CF.

Methods: This was a pre-planned analysis of vitamin D intake in patients enrolled in a multi-center, double-blind, randomized controlled study examining vitamin D therapy for pulmonary exacerbation of CF. Demographic information, responses from a habitual sun exposure questionnaire and food frequency questionnaire, and vitamin D supplement usage were queried and compared to serum 25-hydroxyvitamin D (25(OH)D) concentrations.

Results: A total of 48 subjects were included in this analysis. Subjects were taking approximately 1,200 IU of vitamin D daily. Reported vitamin D intake, age, race, employment, and education were not significantly associated with vitamin D status in this population. However, smoking status, sunlight exposure in the last 3 years, and skin type (in the bivariate model) were all significantly associated with vitamin D status (all p<0.05).

Conclusions: Sunlight exposure was the most predictive determinant of vitamin D status in patients with CF prior to pulmonary exacerbation. Subjects reported vitamin D intake below the recommended amounts. The role and mode of optimizing vitamin D status prior to a pulmonary exacerbation needs further investigation.

Citing Articles

Vitamin D deficiency in patients with cystic fibrosis: a systematic review and meta-analysis.

Farahbakhsh N, Fatahi S, Shirvani A, Motaharifard M, Mohkam M, Tabatabaii S J Health Popul Nutr. 2024; 43(1):11.

PMID: 38233891 PMC: 10795301. DOI: 10.1186/s41043-024-00499-2.


Update on the management of vitamins and minerals in cystic fibrosis.

Sankararaman S, Hendrix S, Schindler T Nutr Clin Pract. 2022; 37(5):1074-1087.

PMID: 35997322 PMC: 9544449. DOI: 10.1002/ncp.10899.


Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis.

Lai H, Chin L, Murali S, Bach T, Sander D, Farrell P Pediatr Pulmonol. 2022; 57(4):935-944.

PMID: 35018747 PMC: 8930603. DOI: 10.1002/ppul.25825.


Vitamin D Status and Risk of Cystic Fibrosis-Related Diabetes: A Retrospective Single Center Cohort Study.

Peng Y, Wu M, Alvarez J, Tangpricha V Nutrients. 2021; 13(11).

PMID: 34836301 PMC: 8619506. DOI: 10.3390/nu13114048.


A Clinician's guide to vitamin D supplementation for patients with cystic fibrosis.

Wood C, Hasan S, Darukhanavala A, Tangpricha V J Clin Transl Endocrinol. 2021; 26:100273.

PMID: 34815946 PMC: 8593649. DOI: 10.1016/j.jcte.2021.100273.

References
1.
Wolfenden L, Judd S, Shah R, Sanyal R, Ziegler T, Tangpricha V . Vitamin D and bone health in adults with cystic fibrosis. Clin Endocrinol (Oxf). 2008; 69(3):374-81. PMC: 2851223. DOI: 10.1111/j.1365-2265.2008.03216.x. View

2.
Vanstone M, Egan M, Zhang J, Carpenter T . Association between serum 25-hydroxyvitamin D level and pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2015; 50(5):441-6. DOI: 10.1002/ppul.23161. View

3.
Elborn J . Cystic fibrosis. Lancet. 2016; 388(10059):2519-2531. DOI: 10.1016/S0140-6736(16)00576-6. View

4.
Brot C, Jorgensen N, Sorensen O . The influence of smoking on vitamin D status and calcium metabolism. Eur J Clin Nutr. 1999; 53(12):920-6. DOI: 10.1038/sj.ejcn.1600870. View

5.
Grossmann R, Tangpricha V . Evaluation of vehicle substances on vitamin D bioavailability: a systematic review. Mol Nutr Food Res. 2010; 54(8):1055-61. PMC: 3033429. DOI: 10.1002/mnfr.200900578. View